Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 3/20 | 0.39 |
| ▸ | GALR2 | O43603 | 2/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041878 | 0.94 | PDGFRB (0.48) | PDGFRBHIF1ACHEK1IDH1GALR2 | |
| SCHEMBL4044890 | 0.91 | CHEK1 (0.49) | PDGFRBCHEK1FLT1KDR | |
| SCHEMBL4047927 | 0.90 | PDGFRB (0.55) | PDGFRBHIF1ACHEK1KDRACHE | |
| SCHEMBL4041668 | 0.89 | CHEK1 (0.42) | PDGFRBHIF1ACHEK1KITFLT1 | |
| SCHEMBL4047352 | 0.89 | PDGFRB (0.48) | PDGFRBHIF1ACHEK1GALR2DHODH | |
| SCHEMBL4044155 | 0.88 | PDGFRB (0.51) | PDGFRBHIF1ACHEK1FLT1KDR | |
| SCHEMBL4041860 | 0.85 | PDGFRB (0.65) | PDGFRBHIF1ACHEK1ACHE | |
| SCHEMBL4047143 | 0.84 | CHEK1 (0.42) | PDGFRBCHEK1KITFLT1KDR | |
| SCHEMBL4046071 | 0.83 | CHEK1 (0.42) | PDGFRBCHEK1KITFLT1KDR | |
| SCHEMBL4047495 | 0.83 | PDGFRB (0.48) | PDGFRBHIF1ACHEK1GALR2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | PDGFRB 2/4885HIF1A 1740/4885CHEK1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.